Hostname: page-component-745bb68f8f-kw2vx Total loading time: 0 Render date: 2025-01-24T06:54:30.186Z Has data issue: false hasContentIssue false
  • English
  • Français

The Frequency of Phospholipid Antibodies in an Unselected Stroke Population

Published online by Cambridge University Press:  18 September 2015

L.M. Metz ,
S. Edworthy ,
R. Mydlarski  and
M.J. Fritzler
L.M. Metz*
Affiliation:
Department of Clinical Neurosciences, Foothills Hospital, University of Calgary
S. Edworthy
Affiliation:
Department of Clinical Neurosciences, Foothills Hospital, University of Calgary
R. Mydlarski
Affiliation:
Department of Clinical Neurosciences, Foothills Hospital, University of Calgary
M.J. Fritzler
Affiliation:
Department of Clinical Neurosciences, Foothills Hospital, University of Calgary
*
12th Floor, Neurology,Foothills Hospital, 1403 - 29th Street N.W., Calgary, Alberta, Canada T2N 2T9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Antibodies to cardiolipin and other phospholipids have been associated with recurrent thrombotic events, including stroke.

Methods:

Over a 16 month period we assessed an unselected cohort of 151 ischemic stroke patients for the presence of antiphospholipid antibodies. Patients with known systemic lupus erythematosis, systemic sclerosis, or Sjogrens Syndrome were excluded. Sera from patients admitted to hospital with a diagnosis of ischemic stroke (n = 151) and from controls (n = 111) assessed during the same period were tested for antiphospholipid antibodies (APLA) using 3 assays; anticardiolipin antibodies (ACA) by ELISA, prolonged activated partial thromboplastin time (APTT), and VDRL.

Results:

The average age of ischemic stroke cases was 68 years (range 29 to 91) and of controls 63 years (range 29 to 86). The prevalence of APLA detected by at least one of the three methods was 12% for IS cases and 10% for controls. After correcting for known risk factors such as age, gender, diabetes mellitus, heart disease, hypertension, and smoking, the odds ratio for risk of stroke fell to 0.8 (C.I. 0.4 to 1.2).

Conclusions:

Our findings suggest that APLA may not be an independent risk factor for ischemic stroke in unselected persons who do not have known systemic lupus erythematosis or systemic sclerosis but further evaluation of the role of lupus anticoagulant is indicated.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue 1 , February 1998 , pp. 64 - 69
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Statistics Canada. Causes of Death Vital Statistics Volume 4, Catalogue. 1986; 84–203.Google Scholar
2.Sahs, AL, Hartman, EC, Aronson, SM. Stroke: Cause, Prevention, Treatment and Rehabilitation. London, Castle House Publication Ltd., 1973; 1–24.Google Scholar
3.The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993; 43: 2069–2073.CrossRefGoogle Scholar
4.Briley, DP, Coull, BM, Goodnight, SH. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989; 25: 221–227.CrossRefGoogle ScholarPubMed
5.Trimble, M, Bell, DA, Brien, W, et al. The antiphospholipid syndrome: prevalence among patients with stroke and transient ischemic attacks. Am J Med 1990; 88: 593–597.CrossRefGoogle ScholarPubMed
6.Kushner, MJ. Prospective study of anticardiolipin antibodies in stroke. Stroke 1990; 21: 295–298.CrossRefGoogle ScholarPubMed
7.Brey, RL, Hart, RG, Sherman, DG, Tegeler, CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190–1196.CrossRefGoogle ScholarPubMed
8.Chakravarty, KK, Byron, MA, Webley, M, et al. Antibodies to cardiolipin in stroke: association with mortality and functional recovery in patients without systemic lupus erythematosus. Q J Med 1991; 397–405.Google ScholarPubMed
9.Hess, DC, Krauss, J, Adams, RJ, et al. Anticardiolipin antibodies: a study of frequency in T1A and stroke. Neurology 1991; 41: 525–528.CrossRefGoogle Scholar
10.Montalban, J, Codina, A, Ordi, J, et al. Antiphospholipid antibodies in cerebral ischemia. Stroke 1991; 22: 750–753.CrossRefGoogle ScholarPubMed
11.Nencini, P, Baruffi, MC, Abbate, R, et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1991; 23: 189–193.CrossRefGoogle Scholar
12.Ginsberg, KS, Liang, MH, Newcomer, L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997–1002.CrossRefGoogle Scholar
13.Levine, SR, Welch, MA. The spectrum of neurologic disease associated with antiphospholipid antibodies. Arch Neurol 1987; 44: 877–883.CrossRefGoogle ScholarPubMed
14.Fields, RA, Tourbeh, H, Searles, RP, Bankhurst, AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989; 16: 623–625.Google Scholar
15.Fritzler, MJ, Pauls, JD, Kinsella, TD, Bowen, TJ. Antinuclear, anticytoplasmic and anti-Sjögren’s syndrome antigen-A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985; 36: 120–128.CrossRefGoogle ScholarPubMed
16.Harris, EN, Gharavi, AE, Patel, SP, Hughes, GRV. Evaluation of the anticardiolipin antibody test: report of a standardization workshop held April 4, 1986. Clin Exp Rheumatol 1987; 3: 349–387.Google Scholar
17.Larsen, SA, Hunter, EF, Kraus, SJ. A Manual of Tests for Syphilis. Washington: American Public Health Association, 1990; 77–91.Google Scholar
18.Ginsberg, JS, Wells, PS, Brill-Edwards, P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86(10): 3685–3691.CrossRefGoogle ScholarPubMed
19.McNeil, HP, Simpson, RJ, Chesterman, CN, Krilis, SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation; β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci 1990; 87: 120–124.CrossRefGoogle ScholarPubMed
20.Galli, M, Comfurius, P, Maassen, C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547.CrossRefGoogle Scholar
21.Koike, T. Anticardiolipin antibodies and β2-glycoprotein I. Clin Immunol Immunopathol 1994; 72: 187–192.CrossRefGoogle Scholar
22.Altman, D.J., Practical Statistics in Medical Research. London: Chapman and Hall, 1991: 169–171.Google Scholar